ANZATAX

This brand name is authorized in Hong Kong SAR China, New Zealand, Singapore, South Africa, Tunisia, Turkey.

Active ingredients

The drug ANZATAX contains one active pharmaceutical ingredient (API):

1	Paclitaxel UNII P88XT4IS4D - PACLITAXEL
	Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions.
	Read more about Paclitaxel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ANZATAX Concentrate for solution for injection	MPI, EU: SmPC	Pharmaceutical Benefits Scheme (AU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CD01	Paclitaxel	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CD Taxanes
Discover more medicines within L01CD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	40639, 40640
NZ	Medicines and Medical Devices Safety Authority	7125
SG	Health Sciences Authority	09539P
TN	Direction de la Pharmacie et du Médicament	11413011H, 11413012H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699643770092, 8699643770108, 8699643770214, 8699643770252
ZA	Health Products Regulatory Authority	36/26/0255